[go: up one dir, main page]

MA30462B1 - Composes de pyridylamide antagonistes des canaux calciques de type t - Google Patents

Composes de pyridylamide antagonistes des canaux calciques de type t

Info

Publication number
MA30462B1
MA30462B1 MA31352A MA31352A MA30462B1 MA 30462 B1 MA30462 B1 MA 30462B1 MA 31352 A MA31352 A MA 31352A MA 31352 A MA31352 A MA 31352A MA 30462 B1 MA30462 B1 MA 30462B1
Authority
MA
Morocco
Prior art keywords
type calcium
calcium channels
compounds
antagonist
pyridylamide compounds
Prior art date
Application number
MA31352A
Other languages
English (en)
Inventor
James C Barrow
Kelly-Ann S Bieber
Rowena V Cube
Mamio Christa Mattern
Thomas S Reger
Youheng Shu
Zhi-Qiang Yang
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of MA30462B1 publication Critical patent/MA30462B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/40—Acylated substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/61—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/65—One oxygen atom attached in position 3 or 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/73—Unsubstituted amino or imino radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D411/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D411/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Anesthesiology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

CETTE INVENTION CONCERNE DES COMPOSÉS DE PYRIDYLAMINE QUI SONT DES ANTAGONISTES DES CANAUX CALCIQUES DE TYPE T ET QUI SONT UTILISÉS POUR LE TRAITEMENT OU LA PRÉVENTION DE TROUBLES ET DE MALADIES DANS LESQUELS LES CANAUX CALCIQUES DE TYPE T INTERVIENNENT. CETTE INVENTION CONCERNE ÉGALEMENT DES COMPOSITIONS PHARMACEUTIQUES RENFERMANT CES COMPOSÉS, AINSI QUE L'UTILISATION DE CES COMPOSÉS ET COMPOSITIONS POUR LA PRÉVENTION OU LE TRAITEMENT DE MALADIES DANS LESQUELLES LES CANAUX CALCIQUES DE TYPE T INTERVIENNENT.
MA31352A 2006-04-12 2008-11-04 Composes de pyridylamide antagonistes des canaux calciques de type t MA30462B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US79137206P 2006-04-12 2006-04-12

Publications (1)

Publication Number Publication Date
MA30462B1 true MA30462B1 (fr) 2009-06-01

Family

ID=38515733

Family Applications (1)

Application Number Title Priority Date Filing Date
MA31352A MA30462B1 (fr) 2006-04-12 2008-11-04 Composes de pyridylamide antagonistes des canaux calciques de type t

Country Status (21)

Country Link
US (2) US7875636B2 (fr)
EP (1) EP2010493B1 (fr)
JP (1) JP5269761B2 (fr)
KR (1) KR20080108539A (fr)
CN (1) CN101466676B (fr)
AU (1) AU2007238755B2 (fr)
BR (1) BRPI0710487A2 (fr)
CA (1) CA2648569C (fr)
CR (1) CR10355A (fr)
DK (1) DK2010493T3 (fr)
EC (1) ECSP088804A (fr)
ES (1) ES2566481T3 (fr)
GT (1) GT200800214A (fr)
IL (1) IL194238A0 (fr)
MA (1) MA30462B1 (fr)
MX (1) MX2008013238A (fr)
NO (1) NO20084769L (fr)
PL (1) PL2010493T3 (fr)
RU (1) RU2008144571A (fr)
WO (1) WO2007120729A2 (fr)
ZA (1) ZA200808024B (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12448369B2 (en) 2023-03-27 2025-10-21 Edgewise Therapeutics, Inc. Quinolinone amide compounds and uses thereof
US12509431B2 (en) 2022-09-26 2025-12-30 Edgewise Therapeutics, Inc. 1,4-dihydroquinazolinone compounds and uses thereof

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2010493T3 (en) * 2006-04-12 2016-05-02 Merck Sharp & Dohme PYRIDYLAMIDE T-TYPE CALCIUM CHANNEL ANTAGONISTS
CA2685753A1 (fr) * 2007-05-09 2008-11-20 Neuromed Pharmaceuticals Ltd. Derives bicycliques de pyrimidine en tant que bloqueurs des canaux calciques
US20100216816A1 (en) * 2007-10-24 2010-08-26 Barrow James C Pyrazinyl amide-t type calcium channel antagonists
US20100249176A1 (en) * 2007-10-24 2010-09-30 Barrow James C Heterocycle amide t-type calcium channel antagonists
CA2701594C (fr) * 2007-10-24 2014-02-18 Merck Sharp & Dohme Corp. Antagonistes de canaux calciques de type t a base de phenyle amide heterocyclique
JP5685203B2 (ja) * 2009-05-29 2015-03-18 ラクオリア創薬株式会社 カルシウムチャネル遮断薬またはナトリウムチャネル遮断薬としてのアリール置換カルボキサミド誘導体
EP2493297B1 (fr) * 2009-10-30 2016-08-17 Merck Sharp & Dohme Corp. Antagonistes des canaux calciques de type t amides hétérocycliques
CA2800521A1 (fr) * 2010-05-24 2011-12-01 Toa Eiyo Ltd. Derive d'imidazole condense
NZ603837A (en) 2010-06-30 2014-01-31 Fujifilm Corp Novel nicotinamide derivative or salt thereof
US9000186B2 (en) 2011-02-01 2015-04-07 Kyowa Hakko Kirin Co., Ltd. Ring-fused heterocyclic derivative
CN102690281A (zh) * 2011-03-22 2012-09-26 上海药明康德新药开发有限公司 1-甲基4-吡唑频哪醇酯的合成方法
AP2013007331A0 (en) * 2011-06-24 2013-12-31 Amgen Inc TRPM8 antagonists and their use in treatments
AU2012278976B2 (en) 2011-07-06 2017-05-11 Gilead Sciences, Inc. Compounds for the treatment of HIV
CN104619707A (zh) 2012-07-31 2015-05-13 协和发酵麒麟株式会社 稠环杂环化合物
TWI694071B (zh) 2013-03-01 2020-05-21 美商基利科學股份有限公司 治療反轉錄病毒科(Retroviridae)病毒感染之治療性化合物
EP2961403A4 (fr) * 2013-03-01 2016-11-30 Zalicus Pharmaceuticals Ltd Inhibiteurs hétérocycliques du canal sodique
US10202353B2 (en) 2014-02-28 2019-02-12 Gilead Sciences, Inc. Therapeutic compounds
EP3150598B1 (fr) 2014-05-28 2019-02-13 TOA Eiyo Ltd. Dérivés de tropane substitués
MA40281B1 (fr) * 2014-06-03 2018-11-30 Idorsia Pharmaceuticals Ltd Composés de pyrazole et leur utilisation en tant qu' agents de blocage des canaux calciques de type t
DE102014109888B4 (de) 2014-07-15 2022-12-01 Karl Storz Se & Co. Kg Verfahren und Vorrichtung zum Prüfen der Licht- und/oder Bildübertragungseigenschaften eines endoskopischen oder exoskopischen Systems
EP3194374B1 (fr) 2014-09-15 2018-08-01 Idorsia Pharmaceuticals Ltd Composés triazole utilisés comme bloqueurs des canaux calciques de type t
WO2017070680A1 (fr) 2015-10-22 2017-04-27 Cavion Llc Procédés pour traiter le syndrome d'angelman et des troubles associés
US11420944B2 (en) 2016-01-12 2022-08-23 Nippon Chemiphar Co., Ltd. Voltage-dependent t-type calcium channel blocker
TWI853404B (zh) 2016-08-19 2024-08-21 美商基利科學股份有限公司 治療性化合物
WO2018106636A1 (fr) * 2016-12-05 2018-06-14 Raze Therapeutics, Inc. Inhibiteurs de shmt et leurs utilisations
PT3554490T (pt) 2016-12-16 2022-03-17 Idorsia Pharmaceuticals Ltd Combinação farmacêutica compreendendo um bloqueador de canais de cálcio de tipo t
US11077115B2 (en) * 2017-01-27 2021-08-03 Genfit Rorgamma modulators and uses thereof
MX376203B (es) 2017-02-06 2025-03-07 Idorsia Pharmaceuticals Ltd Un proceso novedoso para la sintesis de 1-aril-1-trifluoro-metil-ciclopropanos.
US11130750B2 (en) 2017-02-15 2021-09-28 Cavion, Inc. Calcium channel inhibitors
KR102616994B1 (ko) * 2017-04-26 2023-12-26 카비온, 인코포레이티드 드라베 증후군의 치료 방법
IL270180B (en) * 2017-04-26 2022-06-01 Cavion Inc Methods to improve memory and cognition and to treat memory and cognition disorders
AR112412A1 (es) 2017-08-17 2019-10-23 Gilead Sciences Inc Formas de sal de colina de un inhibidor de la cápside del vih
TW202024061A (zh) 2017-08-17 2020-07-01 美商基利科學股份有限公司 Hiv蛋白質膜抑制劑之固體形式
WO2019096762A1 (fr) 2017-11-14 2019-05-23 Albemarle Germany Gmbh Procédé faisant intervenir de l'organolithium dans des conditions de flux en continu
AU2019221568B2 (en) 2018-02-15 2021-04-22 Gilead Sciences, Inc. Pyridine derivatives and their use for treating HIV infection
TWI823164B (zh) 2018-02-16 2023-11-21 美商基利科學股份有限公司 用於製備有療效化合物之方法及中間物
TWI814350B (zh) 2018-07-16 2023-09-01 美商基利科學股份有限公司 用於治療hiv之蛋白殼抑制劑
BR112021006398A2 (pt) * 2018-10-03 2021-07-06 Cavion Inc tratamento de tremor essencial usando (r)-2-(4-isopropilfenil)-n-(1-(5-(2,2,2-trifluoretoxi)piridin-2-il)etil) acetamida
EP3886853A4 (fr) 2018-11-30 2022-07-06 Nuvation Bio Inc. Composés diarylhydantoine et leurs procédés d'utilisation
EP3886854A4 (fr) 2018-11-30 2022-07-06 Nuvation Bio Inc. Composés pyrrole et pyrazole et leurs procédés d'utilisation
BR112022000429A2 (pt) 2019-07-11 2022-03-29 Praxis Prec Medicines Inc Formulações de moduladores do canal de cálcio tipo t e métodos de uso dos mesmos
TWI870475B (zh) * 2019-10-02 2025-01-21 美商卡凡恩公司 用於治療神經毒性之方法及材料
EP4065116B1 (fr) 2019-11-26 2026-01-21 Gilead Sciences, Inc. Inhibiteurs de la capside pour la prevention du vih
TWI858267B (zh) 2020-06-25 2024-10-11 美商基利科學股份有限公司 用於治療hiv之蛋白殼抑制劑
CN116917289A (zh) * 2021-03-04 2023-10-20 小利兰·斯坦福大学董事会 T型钙通道拮抗剂及其用途
MX2023010175A (es) * 2021-03-04 2023-09-07 Univ Leland Stanford Junior Antagonistas de canales de calcio tipo t y usos de los mismos.
AU2022403012B2 (en) 2021-12-03 2026-02-12 Gilead Sciences, Inc. Therapeutic compounds for hiv virus infection
CA3237155A1 (fr) 2021-12-03 2023-06-08 Zhimin Du Composes therapeutiques pour l'infection par le virus du vih
SI4440702T1 (sl) 2021-12-03 2025-09-30 Gilead Sciences, Inc. Terapevtske spojine za okužbo z virusom hiv
WO2024081653A2 (fr) * 2022-10-12 2024-04-18 Acurex Biosciences Corporation Méthodes d'abaissement de miro2 pour traiter des maladies neurodégénératives
IT202200024948A1 (it) * 2022-12-05 2024-06-05 Angelini Pharma S P A Composti attivatori dei canali potassio KV7.2/KV7.3
WO2025255502A1 (fr) 2024-06-07 2025-12-11 Cavion, Inc. Modulateurs du canal pyridyl amide cav3

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA20021A (fr) * 1884-08-18 James H. Blessing Soupape de surete et d'arret
CA19982A (fr) * 1884-08-15 John E. Prest Guide-fil pour machine a filer a boucle
CA20062A (fr) * 1884-08-26 Theodore S. Wilkin Chassis de scies verticales
US2798075A (en) 1957-07-02 Heterocyclic quaternary salts
CA19756A (fr) * 1884-07-08 Perry Fraizer Fut de scie
CA19755A (fr) * 1884-07-08 Louis C. Huber Appareil a signal de chemin de fer
GB782067A (en) 1955-03-21 1957-08-28 Hoffmann La Roche Novel pyridinium salts and a process for the manufacture of same
US3505349A (en) * 1966-04-18 1970-04-07 Hoffmann La Roche 2-nitro-imidazolyl-1-acetamides
CH518290A (de) 1968-01-31 1972-01-31 Bayer Ag Verfahren zur Herstellung von Hydroxyphenazin-di-N-oxiden
US3594982A (en) 1970-04-20 1971-07-27 Kaiser Aluminium Chem Corp Process for drying unsaturated organic gaseous compounds
DE2150279C2 (de) * 1971-10-05 1983-08-25 Schering AG, 1000 Berlin und 4709 Bergkamen Blutzuckersenkende Sulfamoylpyrimidine mit asymmetrischem Kohlenstoffatom
DE3225155A1 (de) * 1982-07-06 1984-01-12 Dr. Karl Thomae Gmbh, 7950 Biberach Neue n-benzylamide und deren salze, ihre herstellung und diese verbindungen enthaltende arzneimittel
DE4443892A1 (de) 1994-12-09 1996-06-13 Bayer Ag 4-(Chinolin-2-yl-methoxy)-phenyl-essigsäurederivate
DE19504379A1 (de) 1995-02-10 1996-08-14 Hoechst Ag Substituierte Benzolsulfonylharnstoffe und -thioharnstoffe, Verfahren zu ihrer Herstellung und ihre Verwendung zur Herstellung pharmazeutischer Präparate sowie sie enthaltende pharmazeutische Präparate
DE19536378A1 (de) 1995-09-29 1997-04-03 Bayer Ag Heterocyclische Aryl-, Alkyl- und Cycloalkylessigsäureamide
FR2751970B1 (fr) * 1996-08-01 1998-08-28 Synthelabo Derives d'acide 6,7,8,9-tetrahydro-5h-imidazo[1,2-a]azepine- 3-acetique, leur preparation et leur application en therapeutique
AUPO252896A0 (en) * 1996-09-24 1996-10-17 Fujisawa Pharmaceutical Co., Ltd. Amidine derivatives
WO1998021185A1 (fr) 1996-11-08 1998-05-22 Sankyo Company, Limited Arylurees ou derives d'arylmethylcarbamyle
GB9828442D0 (en) * 1998-12-24 1999-02-17 Karobio Ab Novel thyroid receptor ligands and method II
GB9919588D0 (en) 1999-08-18 1999-10-20 Hoechst Schering Agrevo Gmbh Fungicidal compounds
MXPA02008797A (es) 2000-03-14 2005-09-08 Actelion Pharmaceuticals Ltd Derivados de 1,2,3,4-tetrahidroisoquinolina.
UA75093C2 (en) 2000-10-06 2006-03-15 Dimensional Pharm Inc Aminopyridinyl-,aminoguanidinyl-, and alkoxyguanidinesubstituted phenylsubstituted phenylacetamides as protease inhibitors
WO2002051232A2 (fr) 2000-12-27 2002-07-04 Actelion Pharmaceuticals Ltd. Nouvelles benzazepines et derives heterocycliques associes
CA2435492A1 (fr) 2001-02-02 2002-08-15 Boehringer Ingelheim Pharma Gmbh & Co. Kg Composes antithrombotiques, leur preparation et leur utilisation comme produits pharmaceutiques
US6610701B2 (en) * 2001-02-09 2003-08-26 Merck & Co., Inc. Thrombin inhibitors
US20020183519A1 (en) 2001-03-13 2002-12-05 Herbert Nar Antithrombotic carboxylic acid amides
CN100408564C (zh) 2001-04-10 2008-08-06 美国辉瑞有限公司 治疗hiv的吡唑衍生物
GB0115109D0 (en) 2001-06-21 2001-08-15 Aventis Pharma Ltd Chemical compounds
DE10130397A1 (de) * 2001-06-23 2003-01-09 Bayer Cropscience Gmbh Herbizide substituierte Pyridine, Verfahren zu ihrer Herstellung und ihre Verwendung als Herbzide und Pflanzenwachstumsregulatoren
EP1427408A4 (fr) * 2001-09-17 2005-10-26 Bristol Myers Squibb Co Acides hydroxamiques cycliques utilises comme inhibiteurs de metalloproteinases matricielles et/ou d'enzyme de conversion du tnf-$g(a) (tace)
US20030158218A1 (en) * 2001-12-21 2003-08-21 Nantermet Philippe G. Thrombin inhibitors
US20030199523A1 (en) 2002-02-28 2003-10-23 Snutch Terrance P. Heterocyclic calcium in channel blockers
DE10209766B4 (de) * 2002-03-05 2004-02-19 Daimlerchrysler Ag Komponententausch-Warnsystem
TW200508197A (en) 2003-03-31 2005-03-01 Ucb Sa Indolone-acetamide derivatives, processes for preparing them and their uses
KR20060115753A (ko) 2003-12-22 2006-11-09 머크 앤드 캄파니 인코포레이티드 브라디키닌 길항제 또는 역 효능제로서의 알파-하이드록시아미드
US7569604B2 (en) 2004-06-22 2009-08-04 Vertex Pharmaceuticals Incorporated Heterocyclic derivatives for modulation of calcium channels
DE102004041137A1 (de) * 2004-08-25 2006-03-02 Wella Ag o-Aminophenol-Derivate und diese Verbindungen enthaltende Färbemittel
AU2005286525B2 (en) 2004-09-22 2011-06-16 Janssen Pharmaceutica N.V. Inhibitors of the interaction between MDM2 and p53
CN101228129A (zh) 2005-04-20 2008-07-23 詹森药业有限公司 氟代吡啶n-氧化物凝血酶调节剂和含氮杂芳基化合物的n-氧化方法
EP1762218A1 (fr) 2005-08-30 2007-03-14 Wella Aktiengesellschaft Dérivés de 4-aminphénol et colorants les contenant
EP1760072A1 (fr) 2005-08-30 2007-03-07 Wella Aktiengesellschaft Dérivés du 1,3-diaminobenzène et agents colorants comprenant ces composés
CA2634442A1 (fr) 2005-12-22 2007-07-05 Icagen, Inc. Antagonistes du canal calcique
US7671061B2 (en) * 2005-12-22 2010-03-02 Hydra Biosciences, Inc. Methods and compositions for treating pain
DK2010493T3 (en) 2006-04-12 2016-05-02 Merck Sharp & Dohme PYRIDYLAMIDE T-TYPE CALCIUM CHANNEL ANTAGONISTS
SI3034075T1 (sl) 2006-11-22 2018-12-31 Incyte Holdings Corporation Imidazotriazini in imidazopirimidini kot inhibitorji kinaze
US8573228B2 (en) 2007-09-20 2013-11-05 Medtronic, Inc. Needle to port trajectory indicator
US20100249176A1 (en) 2007-10-24 2010-09-30 Barrow James C Heterocycle amide t-type calcium channel antagonists
CA2701594C (fr) 2007-10-24 2014-02-18 Merck Sharp & Dohme Corp. Antagonistes de canaux calciques de type t a base de phenyle amide heterocyclique
US20100216816A1 (en) 2007-10-24 2010-08-26 Barrow James C Pyrazinyl amide-t type calcium channel antagonists

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12509431B2 (en) 2022-09-26 2025-12-30 Edgewise Therapeutics, Inc. 1,4-dihydroquinazolinone compounds and uses thereof
US12448369B2 (en) 2023-03-27 2025-10-21 Edgewise Therapeutics, Inc. Quinolinone amide compounds and uses thereof

Also Published As

Publication number Publication date
ES2566481T3 (es) 2016-04-13
CA2648569C (fr) 2012-02-07
AU2007238755A1 (en) 2007-10-25
CN101466676A (zh) 2009-06-24
WO2007120729A2 (fr) 2007-10-25
US8263627B2 (en) 2012-09-11
ZA200808024B (en) 2009-11-25
PL2010493T3 (pl) 2016-08-31
KR20080108539A (ko) 2008-12-15
RU2008144571A (ru) 2010-05-20
US20090275550A1 (en) 2009-11-05
JP2009534320A (ja) 2009-09-24
US7875636B2 (en) 2011-01-25
EP2010493B1 (fr) 2016-01-27
CN101466676B (zh) 2012-07-18
MX2008013238A (es) 2008-10-21
CA2648569A1 (fr) 2007-10-25
WO2007120729A3 (fr) 2008-01-03
BRPI0710487A2 (pt) 2012-06-05
IL194238A0 (en) 2009-09-22
JP5269761B2 (ja) 2013-08-21
AU2007238755B2 (en) 2012-07-12
US20110112064A1 (en) 2011-05-12
NO20084769L (no) 2009-01-07
CR10355A (es) 2008-10-29
GT200800214A (es) 2009-02-25
EP2010493A2 (fr) 2009-01-07
ECSP088804A (es) 2008-11-27
DK2010493T3 (en) 2016-05-02

Similar Documents

Publication Publication Date Title
MA30462B1 (fr) Composes de pyridylamide antagonistes des canaux calciques de type t
MA32804B1 (fr) Antagonistes d'isonicotinamide des récepteurs de l'orexine
MA31016B1 (fr) Composes de diazepan substitues comme antagonistes des recepteurs de l'orexine.
MA57825B1 (fr) Tétrahydrofuranes substitués en tant que modulateurs de canaux sodiques
IL185391A0 (en) Quinazolinone t-type calcium channel antagonists
MA33604B1 (fr) Composés et compositions en tant qu'inhibiteurs de protéine kinase
MA35460B1 (fr) Composés et compositions en tant qu'inhibiteurs de kinase c-kit
MA34969B1 (fr) Composes et compositions en tant qu inibiteurs de trk
MA32031B1 (fr) Procedes et compositions faisant appel a des polypeptides de fusion klotho-fgf
MA30906B1 (fr) Composes et compositions en tant quinhibiteurs des proteines kinases
MA30772B1 (fr) Composes et compositions utilises en tant qu'inhibiteurs de proteine kinase
TNSN07161A1 (en) Compounds and compositions as inhibitors of cannabinoid receptor 1 activity
MA30340B1 (fr) Nouveaux composes
MA34655B1 (fr) Dérivés de 2,3- dihydroimidazo[1,2-c]quinazoléine substitués par un aminoalcool utiles pour traiter des troubles hyperprolifératifs et des maladies associées à l'angiogenèse
MA30041B1 (fr) Immunoglobulines
MY145077A (en) Pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
MA30539B1 (fr) Derives de piperazinyle utiles dans le traitement de maladies induites par le recepteur gpr38.
MA31502B1 (fr) Anticorps anti-notch 1 specifiques a nrr et ses procedes d'utilisation
MA31767B1 (fr) Composes organiques et leurs utilisations
TW200612926A (en) Compounds and compositions as ppar modulators
DE69626818D1 (de) Zusammensetzung welche einen darmbakterienstamm und glutamin enthält
MA39359A1 (fr) Composés d'isoindolinone utilisés comme modulateurs de gpr119 pour le traitement du diabète, de l'obésité et de troubles associés
MA31941B1 (fr) Bis-pyridylpyridones en tant qu'antagonistes du récepteur 1 de l'hormone de concentration de la mélanine
MA58049B1 (fr) Antagonistes du récepteur du sous-type 2 de la mélanocortine (mc2r) à pipéridine à double substitution gem et leurs utilisations
MX2024011254A (es) Moduladores de nlrp3